Frankfurt - Delayed Quote EUR

ABIVAX Société Anonyme (2X10.F)

5.55

+0.05

+(0.91%)

At close: 8:16:34 AM GMT+1

Abivax Publishes 2025 Financial Calendar

Abivax Publishes 2025 Financial Calendar PARIS, France – January 28, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today published its expected 2025 financial communications calendar. Monday, March 24, 2025 (after US Market closes) 2024 Annual Business and Financial Report (as of December 31, 2024) Press ReleaseUnivers

GlobeNewswire 3 days ago

AAVXF

ABVX
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress PARIS, France – January 23, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced that seven scientific abstracts on its lead drug candidate, obefazimod,

GlobeNewswire 8 days ago

AAVXF

ABVX
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion expected in Q2 2025.Top-line results for the 8-week induction trial anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026.Blinded baseline characteristics ali

GlobeNewswire 22 days ago

AAVXF

ABVX
Abivax Announces a Change to the Composition of its Board of Directors

Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced that Dr. Philippe Pouletty, representative of Truffle Capital, tendered his re

GlobeNewswire last month

AAVXF

ABVX
Why ABIVAX Société Anonyme (ABVX) is the Best All-Time Low Stock to Buy Right Now?

We recently published a list of 10 Best All-Time Low Stocks To Buy Right Now. In this article, we are going to take a look at where ABIVAX Société Anonyme (NASDAQ:ABVX) stands against other best all-time low stocks to buy right now. With November coming to a close, while markets are focused on the future […]

Insider Monkey last month

ABVX.PA
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (“ATM Program”) allow

GlobeNewswire 2 months ago

AAVXF

ABVX
Abivax presents third quarter 2024 key financial information

Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30,

GlobeNewswire 2 months ago

AAVXF

ABVX
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observ

GlobeNewswire 2 months ago

AAVXF

ABVX
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, is thrilled to

GlobeNewswire 3 months ago

AAVXF

ABVX
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX; Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the first patient was enro

GlobeNewswire 3 months ago

AAVXF

ABVX
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated with a de-escalated dose of 25 mg of obefazimod once daily demonstrated maintenance of clinical remission at weeks 48 and 96Efficacy and safety demonstrated out to six years of treatment The treatment was well-tolerated, with a safety profile consistent with previous studies and no new safety signals

GlobeNewswire 3 months ago

AAVXF

ABVX
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC)Two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96 of an open-label

GlobeNewswire 4 months ago

AAVXF

ABVX
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model Abivax is actively conducting preclinical studies with multiple oral and injectable therapies and will report additional data in Q4 2024.Pre-clinical evaluation of obefazimod combined with etrasimod improved body weight protection and Disease Activity Index with a synergistic and statist

GlobeNewswire 4 months ago

AAVXF

ABVX
Abivax presents first-half 2024 financial results

Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to Q4 2025 PARIS, France, September 9, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its 2024 half-year fin

GlobeNewswire 4 months ago

AAVXF

ABVX
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient enrollment milestone confirming ABTECT currently on pace to reach full enrollment in early Q1 2025To date, baseline participants baseline characteristics and trial trends in line with observations from Phase 2b trial PARIS, France, August 6, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: A

GlobeNewswire 5 months ago

AAVXF

ABVX
Abivax Provides Operational and Key Program Update

Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire name

GlobeNewswire 6 months ago

AAVXF

ABVX
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “General Meeting”), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Direct

GlobeNewswire 7 months ago

AAVXF

ABVX
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms ...

ACCESS Newswire 11 months ago

AAVXF

ABVX

Performance Overview

Return	2X10.F	CAC 40
YTD	-13.95%	+8.70%
1-Year	-53.75%	+3.55%
3-Year	-34.32%	+14.13%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ABIVAX Société Anonyme (2X10.F)

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces a Change to the Composition of its Board of Directors

Why ABIVAX Société Anonyme (ABVX) is the Best All-Time Low Stock to Buy Right Now?

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Abivax presents first-half 2024 financial results

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Abivax Provides Operational and Key Program Update

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)

Performance Overview